Stephen Thau

Stephen Thau

Morrison & Foerster LLP

Contact  |  View Bio  |  RSS

Latest Publications

Share:

MoFo BioMeter - Vol. 3, Issue 3, August 2014 - Q2 Biometer Shows Strong Value In Drug Discovery Platforms

The average BioMeter value in the second quarter of 2014 jumped significantly to $143.4 million, an increase from the $15.9 million value in the first quarter. This included two blockbuster deals, the $1 billion up front paid...more

8/8/2014 - Bayer Biotechnology Merck Pfizer Pharmaceutical Prescription Drugs

MoFo BioMeter - Vol. 3, Issue 2, May 2014 - Early Stage Deals Dominant Q1: Uptick in total dealmaking activity compared with same...

The MoFo BioMeter for the first quarter of 2014 shows a decrease in average BioMeter value in a quarter dominated by early stage deals. Total dealmaking activity showed an uptick compared to the same quarter in...more

5/14/2014 - Biotechnology Pharmaceutical Technology

MoFo BioMeter - Vol. 3, Issue 1, March 2014 - Q4 and FY 2013 BioMeter Shows Rebound in Value for Late Stage Products and Strong...

The full-year 2013 BioMeter analysis shows across-the-board increases in BioMeter value, with an average of $33.9 million for all transactions, up from approximately $21.2 million in 2012. Increases occurred for each stage of...more

3/28/2014 - Pharmaceutical Prescription Drugs

MoFo BioMeter - Vol. 2, Issue 4, November 2013 - Q3 BioMeter Shows Strong Early Stage Deals

The average BioMeter value in the third quarter of 2013 was $30.4 million, an increase from the $22.2 million value in the second quarter. Like last quarter, Phase 1 and Phase 2 transactions showed very strong results, with...more

11/26/2013 - Biotechnology Pharmaceutical Prescription Drugs

MoFo BioMeter - Vol. 2, Issue 3, August 2013 - Q2 BioMeter Encouraging for Products from Early Development through Phase 2

The average BioMeter value in the second quarter of 2013 was $22.2 million, an increase from the $16.3 million value in the first quarter (excluding BMS/Rickets and AZ/Moderna), and down from $59.4 million in the first...more

8/29/2013 - Biotechnology Pharmaceutical

MoFo BioMeter - Volume 2, Issue 2: May 2013 - Flat BioMeter Value and Decline in Deal Volume are Hallmarks of Q1

The Morrison & Foerster BioMeter for the first quarter of 2013 shows a flat quarter for BioMeter value and a decline in dealmaking activity. A small number of large deals dominate an otherwise quiet quarter. In the...more

5/31/2013 - Biotechnology OTC Pharmaceutical Prescription Drugs Valuation

MoFo BioMeter - Volume 2, Issue 2: May 2013 - Flat BioMeter Value and Decline in Deal Volume are Hallmarks of Q1

The Morrison & Foerster BioMeter for the first quarter of 2013 shows a flat quarter for BioMeter value and a decline in dealmaking activity. A small number of large deals dominate an otherwise quiet quarter. In the...more

5/22/2013 - Biotechnology

MoFo BioMeter - Volume 2, Issue 1: February 2013

Phase 2 Deals Dominate Q4 and Full Year 2012 - Morrison & Foerster is pleased to release the MoFo BioMeter for the fourth quarter of 2012 and for the full year of 2012. The fourth quarter of 2012 saw an uptick in...more

2/25/2013 - Biotechnology Life Sciences

Introducing the MoFo BioMeter

Morrison & Foerster is pleased to introduce the MoFo BioMeterâ„¢, an index developed to measure the health of the biotechnology industry. BioMeter takes the pulse of the industry by looking at a key measure of deal...more

12/15/2012 - Biotechnology Life Sciences

9 Results
|
View per page
Page: of 1